ArticleEuropean heart journal. Case reports2026
A case report of an S-ICD-recorded asystole due to SMART pass deactivation in a patient with non-obstructive hypertrophic cardiomyopathy.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The SMART pass (SP) algorithm of the subcutaneous implantable cardioverter-defibrillator (S-ICD; Boston Scientific Emblem) uses a high-pass filter to reduce inappropriate shocks due to signal oversensing. In cases of small to no R-wave amplitude, the SP algorithm is automatically deactivated, and an electrocardiogram (ECG) is recorded. Case Summary: A 63-year-old patient with hypertrophic cardiomyopathy (HCM) without left ventricular outflow tract obstruction underwent implantation of an S-ICD. When the patient reported syncope months later, device interrogation revealed SP deactivation due to a 22-second asystole, consistent with the timing of the syncope. Prior to the event, there was no indication of future pacing requirement. The patient had a stable two-vessel coronary artery disease as well as unaltered echocardiographic findings, including preserved left ventricular ejection fraction. The S-ICD was replaced by a transvenous dual-chamber implantable cardioverter-defibrillator. Discussion: Although bradycardia detection is not available in the S-ICD system, in our case, it was enabled due to ECG recording performed during SP deactivation, which outlines the importance of careful investigation. Since bradyarrhythmia in HCM is considered rare, it has been studied far less extensively than atrial and ventricular tachyarrhythmia. There is substantial evidence that myocardial fibrosis is a significant predictor of ventricular tachycardia and sudden cardiac death. However, more extended research is required to further investigate the association between myocardial fibrosis and bradyarrhythmia in patients with HCM, as well as to evaluate the potential of magnetic resonance imaging-based screening to identify patients at risk requiring future pacing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.